Physician profile
Daisy Batista
NPI 1598892929
$1,787.67
in general payments reported to CMS, 2019-2025
14 companies · $718 in 2025
The $718 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.47 · 2023: $524 · 2024: $531 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,727 · Education: $46.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,726.69 |
| Education | $46.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $371.96 | 2023-2025 | Tremfya, Stelara |
| Abbvie INC. | $236.43 | 2023 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $235.02 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $167.19 | 2023-2025 | Entyvio |
| E.R. Squibb & Sons, L.L.C. | $125.01 | 2024 | Zeposia |
| Ardelyx, INC. | $125.00 | 2025 | Ibsrela |
| Gilead Sciences, INC. | $125.00 | 2025 | Livdelzi |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Aimmune Therapeutics, INC. | $123.21 | 2024 | |
| Janssen Scientific Affairs, LLC | $92.87 | 2025 | Tremfya |
| Pfizer INC. | $30.40 | 2024 | |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Intercept Pharmaceuticals, INC. | $14.47 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daisy Batista listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.